Compare DNOW & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNOW | NRIX |
|---|---|---|
| Founded | 1862 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 2014 | 2020 |
| Metric | DNOW | NRIX |
|---|---|---|
| Price | $14.23 | $23.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $16.67 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 3.0M | 1.9M |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,648,000,000.00 | $76,987,000.00 |
| Revenue This Year | $69.47 | N/A |
| Revenue Next Year | $8.01 | $48.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.68 | ★ 99.31 |
| 52 Week Low | $10.94 | $8.20 |
| 52 Week High | $17.26 | $25.09 |
| Indicator | DNOW | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 66.95 | 62.87 |
| Support Level | $13.73 | $14.63 |
| Resistance Level | $14.31 | $24.98 |
| Average True Range (ATR) | 0.36 | 1.22 |
| MACD | 0.14 | -0.27 |
| Stochastic Oscillator | 98.08 | 62.00 |
Dnow Inc is a provider of energy and industrial solutions and a distributor of pipe, valves, and fittings (PVF) and pumps, as well as fabrication, assembly, and testing of process and production equipment. It provides a broad mix of products required to build and maintain essential infrastructure and operating equipment across upstream, midstream, gas utilities, downstream, energy transition, and industrial markets, along with value-added supply chain solutions and technical product expertise supported by digital offerings through its DigitalNOW and MRCGO e-commerce platforms. The company operates mainly under the DNOW and MRC brands and has three reportable segments: the United States, which generates the majority of revenue, Canada, and International.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.